Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection.
A sensitive reversed-phase HPLC method for the analysis of olanzapine in human plasma is described. Isolation of olanzapine from plasma was accomplished by solid-phase extraction utilizing an ion-exchange/reversed-phase cartridge designed for basic drug extraction. The drug was subsequently separated by reversed-phase HPLC and monitored by electrochemical detection (ED). Electrochemical analysis was used to detect olanzapine due to its uniquely low oxidative potential. Ascorbic acid was added to prevent oxidation during extraction. The limit of quantitation for the assay was established at 0.25 ng/ml utilizing a 1-ml human plasma sample. The average inter-day accuracy was 96.6% with a average precision (% C.V.) of 3.22% over the concentration range of 0.25 to 100 ng/ml. This method was applied to human plasma samples from human clinical trials with olanzapine. The HPLC-ED method compared favorably with a negative chemical ionization GC-MS method previously utilized for analysis of olanzapine in human plasma.
Catlow
J T
JT
Lilly Research Laboratories, Department of Drug Metabolism and Disposition, Indianapolis, IN 46285, USA.
Barton
R D
RD
Clemens
M
M
Gillespie
T A
TA
Goodwin
M
M
Swanson
S P
SP
D014150:Antipsychotic Agents / Q000097:blood*; D001569:Benzodiazepines; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004563:Electrochemistry; D006801:Humans; D000077152:Olanzapine; D010084:Oxidation-Reduction; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000097:blood; D015203:Reproducibility of Results
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine